Drug intelligence / Profile preview

proparacaine 0.05%

Development stage
Unknown
Lead developer
London Health Sciences Centre
Modality
Small Molecules
Administration
Ophthalmic, Topical
01

Overview

Proparacaine 0.05% is a dilute topical ophthalmic anesthetic formulation being investigated by the London Health Sciences Centre for the management of acute pain in patients with traumatic corneal injuries, such as corneal abrasions. While standard proparacaine (0.5%) is typically restricted to clinical settings due to the risk of corneal toxicity (keratopathy) with repeated use, this low-concentration formulation is designed for safe, short-term outpatient use. Proparacaine is a small molecule ester-class local anesthetic that functions by blocking voltage-gated sodium channels in the nerve cell membranes of the corneal surface. This action inhibits the initiation and conduction of nerve impulses, providing rapid and effective local anesthesia to alleviate the significant distress and pain associated with corneal surface damage.

Other names
dilute proparacaineproparacaine hydrochloride 0.05%topical proparacaine
02

Targets

ENaCSCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)SCN10A (Sodium channel protein type X alpha subunit)

Beyond the preview

Go deeper on proparacaine 0.05%.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on proparacaine 0.05%.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call